99% Min Purity Tafluprost Inhibitor PGF2a Analog Cas 209860-87-7

Description:

Travoprost is a PGF2a analog that was launched as an ophthalmic solution administered topically for the treatment of elevated intraocular hypertension as a result of open-angle glaucoma, a common optic neuropathy, and a leading cause of blindness. It can act as an agonist of prostaglandin F receptor.

Targets:

prostaglandin F receptor (HEK-293 cells)

42.3 nM(EC50)

Related Prodcuts:

Latanoprost Lactol; trans-(15S)-Latanoprost; Latanoprostene bunod; 15(S)-Latanoprost; trans-Latanoprost; (+)-Cloprostenol; Cloprostenol; Misoprostol; Carboprost; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Iloprost; Limaprost; Bimatoprost;

[1]. Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.

[2]. Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.

[3]. Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6.